According to IMARC Group’s latest report “Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026.’ the global acute myeloid leukemia therapeutics market grew at a CAGR of around 7% during 2015-2020. Acute myeloid leukemia (AML) therapeutics are used to treat AML, a type of bone marrow and blood cancer leading to the rapid growth of abnormal cells. Some commonly used AML therapeutics include chemo, radiation and hormonal therapy, stem cell transplant, targeted drug therapies, and leukapheresis. They help identify and attack cancer cells precisely, strengthen the immunity system, reduce post-treatment complications, and minimize the chances of cancer relapse.
|Also Read: Global Chlor-Alkali Market|
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report
The global acute myeloid leukemia therapeutics market is primarily driven by the widespread disease prevalence due to the aging population, prolonged exposure to hazardous chemicals, and unhealthy lifestyles. Additionally, the growing awareness regarding available AML treatment options, such as combination, immuno-, and targeted therapies, has catalyzed the product demand. Furthermore, the introduction of improved immunotoxins, monoclonal antibodies, and multidrug-resistant modulators to offer enhanced results and efficacy has accelerated product adoption rates. Other factors, including the rising approval of novel and innovative drugs, ongoing research and development (R&D) activities, increasing government funding, and improving healthcare infrastructure, are also anticipated to propel the market growth. Looking forward, IMARC Group expects the global acute myeloid leukemia therapeutics market to exhibit moderate growth during the next five years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, drug type and route of administration.
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Roche Holding AG
- Gilead Sciences Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Takeda Pharmaceutical Company Limited.
Breakup by Treatment Type:
- Anthracycline Drugs
- Alkylating Agents
- Tyrosine Kinase Inhibitors
Breakup by Drug Type:
- Small Molecule Drugs
Breakup by Route of Administration:
Breakup by Region:
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.